Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.

[1]  J. Oxford,et al.  Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  UK stocks up on antiviral drug to tackle flu outbreak , 2005, BMJ : British Medical Journal.

[3]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.

[4]  R. Balicer,et al.  Tackling the next influenza pandemic , 2004, BMJ : British Medical Journal.

[5]  R. Webster,et al.  The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. , 2000, Antiviral research.

[6]  J. Fleiss,et al.  The measurement of interrater agreement , 2004 .

[7]  N E Breslow,et al.  Elementary methods of cohort analysis. , 1984, International journal of epidemiology.

[8]  A. Monto,et al.  Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. , 1999, JAMA.

[9]  S. Lazzari,et al.  Avian influenza and influenza pandemics. , 2004, Bulletin of the World Health Organization.

[10]  A. Sutton,et al.  Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials , 2003, BMJ : British Medical Journal.

[11]  P. Ward,et al.  Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. , 2003, Archives of internal medicine.

[12]  World is ill-prepared for "inevitable" flu pandemic. , 2004, Bulletin of the World Health Organization.

[13]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[14]  C. DesRoches,et al.  The public's response to severe acute respiratory syndrome in Toronto and the United States. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  F. Hayden,et al.  Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. , 1989, The New England journal of medicine.

[16]  L. Huson,et al.  Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. , 1999, The New England journal of medicine.

[17]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[18]  H. Oshitani,et al.  Detection of Amantadine-Resistant Influenza A Virus Strains in Nursing Homes by PCR-Restriction Fragment Length Polymorphism Analysis with Nasopharyngeal Swabs , 2002, Journal of Clinical Microbiology.

[19]  C. Perry,et al.  Oseltamivir , 2012, Drugs.

[20]  WHO consultation on priority public health interventions before and during an influenza pandemic, Geneva, 16-18 March 2004. , 2004, Releve epidemiologique hebdomadaire.